FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma

[FDA]

On December 22, 2022, the Food and Drug Administration (FDA) granted accelerated approval to mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL).


Baca selengkapnya di : http://www.fda.gov...